Ultragenyx Pharmaceutical announced that Eric Crombez, M.D., has been promoted to chief medical officer and executive vice president effective May 1, 2023, succeeding Camille Bedrosian, M.D., who will remain with the company in a full-time strategic advisory role. Dr. Crombez currently serves as Ultragenyx’s chief medical officer for gene therapy and inborn errors of metabolism.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
- Ultragenyx price target raised to $57 from $50 at Baird
- Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Ultragenyx reports Q4 EPS ($2.16), consensus ($2.14)
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update